Truxima IV / Herzuma IVBiosimilars MarketMonoclonal antibodiesLaunches

Launch of Ofev a new drug for the treatment of idiopathic pulmonary fibrosis (rare disease)

Objectives:*Relaunch an anthithrombotic / Platelet aggregation inhibitor to limit market share erosion*Drive growth for mature product (antiplatelet agent)Achievements:*anthithrombotic / Platelet aggregation inhibitor : Maintained market share (Y+1)*antiplatelet agent : Gained +1 point of market share in the antiplatelet market (Y+1)Key Responsibilities:*Operational: Developed, implemented, and managed promotional tools (sales arguments, product and environment visit materials, etc.). Briefed agencies, monitored stock levels, tracked sales/forecasts, and participated in congresses*Strategic: Participated to developed the 2016 BSP*Presentations: Delivered presentations at seminars, regional manager meetings, sales force training, and led team meetings*CRM: Led the "Direct Marketing" project, including database qualification and performance tracking*Digital: Launched a new website (strategy development, and synergies with another business unit).*MCM: Trained and developed multichannel strategies for both products.*Field: Managed the "marketing/sales" relationships (hospital & based office commercial field force), including duo.

• Aid in campaign preparation for the 3 drugs (different levels in the life cycle drug management: launch, growing and established)• Update of promotional tools• Design of new innovative supports for the sales force• Digital: promotion of an health mobile application for patients suffering from HBP

• Use of a software called "Sterigest" for the traceability• Quality controls• Audit of some blocks (cardiology, digestive) in order to improve the traceability of medical devices

• Prescriptions analysis• Visiting patients with physicians